NASDAQ:APEN - Apollo Endosurgery Stock Price, Forecast & News

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APEN stock has decreased by 10.9% and is now trading at $1.84. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Apollo Endosurgery.

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Monday, March 30th 2020. View our earnings forecast for Apollo Endosurgery.

Apollo Endosurgery Inc (NASDAQ:APEN) released its quarterly earnings data on Thursday, March, 26th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.04. Apollo Endosurgery had a negative return on equity of 237.39% and a negative net margin of 54.09%. View Apollo Endosurgery's earnings history.

1 Wall Street analysts have issued 12 month price targets for Apollo Endosurgery's stock. Their forecasts range from $4.50 to $4.50. On average, they anticipate Apollo Endosurgery's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 144.6% from the stock's current price. View analysts' price targets for Apollo Endosurgery.

Media stories about APEN stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutApollo Endosurgery.

Apollo Endosurgery saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 181,900 shares, an increase of 31.7% from the February 13th total of 138,100 shares. Based on an average daily volume of 14,700 shares, the days-to-cover ratio is currently 12.4 days. Approximately 1.5% of the shares of the stock are sold short. View Apollo Endosurgery's Current Options Chain.

Some companies that are related to Apollo Endosurgery include Restoration Robotics (HAIR), Accuray (ARAY), Soliton (SOLY), Pulse Biosciences (PLSE), Liquidia Technologies (LQDA), Apyx Medical (APYX), RenovaCare (RCAR), Venus Concept (VERO), BeyondAirInc . (XAIR), TELA Bio (TELA), AIT Therapeutics (AITB), Spectral Medical (EDTXF), BRAINSWAY LTD/S (BWAY), PAVmed (PAVM) and Pro-Dex (PDEX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Onconova Therapeutics (ONTX), Corbus Pharmaceuticals (CRBP), Second Sight Medical Products (EYES), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Apollo Endosurgery's stock is owned by a number of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (4.77%), Renaissance Technologies LLC (0.41%), Russell Investments Group Ltd. (0.36%) and University of Texas Texas AM Investment Managment Co. (0.07%). Company insiders that own Apollo Endosurgery stock include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View institutional ownership trends for Apollo Endosurgery.

APEN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. View insider buying and selling activity for Apollo Endosurgery.

APEN stock was bought by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, University of Texas Texas AM Investment Managment Co., and Renaissance Technologies LLC. Company insiders that have bought Apollo Endosurgery stock in the last two years include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP, and Todd Newton. View insider buying and selling activity for Apollo Endosurgery.

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APEN stock can currently be purchased for approximately $1.84.

Apollo Endosurgery has a market capitalization of $38.53 million and generates $50.71 million in revenue each year. The biotechnology company earns $-27,430,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe. View additional information about Apollo Endosurgery.

The official website for Apollo Endosurgery is http://www.apolloendo.com/.

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]